NEW YORK — Immune profiling firm Immunai said on Thursday that it has raised $60 million in a Series A funding round.
The Tel Aviv- and New York City-based company said it plans to use the funds to expand its Annotated Multi-omic Immune Cell Atlas (AMICA) and to extend its functional genomics capabilities to reprogram immune cells and validate drug targets.
The round was led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma with existing investors Viola Ventures and TLV Partners also participating.